Keys to drug sensitivity from updated functional work flows
Open Access
- 1 June 2020
- journal article
- editorial
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 105 (6), 1468-1470
- https://doi.org/10.3324/haematol.2020.250662
Abstract
Cancer cells undergo massive alterations in their DNA methylation patterns which result in aberrant gene expression and malignant phenotypes. Abnormal DNA methylation is a prognostic marker in several malignancies, but its potential prognostic significance in adult T-cell acute lymphoblastic leukemia (T-ALL) is poorly defined. Here, we performed methylated DNA immunoprecipitation to obtain a comprehensive genome-wide analysis of promoter methylation in adult T-ALL (n=24) compared to normal thymi (n=3). We identified a CpG hypermethylator phenotype that distinguishes two T-ALL subgroups and further validated it in an independent series of 17 T-lymphoblastic lymphoma. Next, we identified a methylation classifier based on nine promoters which accurately predict the methylation phenotype. This classifier was applied to an independent series of 168 primary adult T-ALL treated accordingly to the GRAALL03/05 trial using methylation-specific multiplex ligation-dependent probe amplification. Importantly hypomethylation correlated with specific oncogenic subtypes of T-ALL and identified patients associated with a poor clinical outcome. This methylation-specific multiplex ligation-dependent probe amplification based methylation profiling could be useful for therapeutic stratification of adult T-ALL in routine practice. The GRAALL-2003 and -2005 studies were registered at http://www.clinicaltrials.gov as #NCT00222027 and #NCT00327678, respectively.This publication has 7 references indexed in Scilit:
- Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid LeukemiaCancer Discovery, 2020
- Multi-parametric single cell evaluation defines distinct drug responses in healthy hematologic cells that are retained in corresponding malignant cell typesHaematologica, 2019
- Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemiaHaematologica, 2019
- Precision medicine for cancer with next-generation functional diagnosticsNature Reviews Cancer, 2015
- Individualized Systems Medicine Strategy to Tailor Treatments for Patients with Chemorefractory Acute Myeloid LeukemiaCancer Discovery, 2013
- BCL-2 Inhibition Targets Oxidative Phosphorylation and Selectively Eradicates Quiescent Human Leukemia Stem CellsCell Stem Cell, 2013
- Stems Cells and the Pathways to Aging and CancerCell, 2008